Tag Archive for: kidney cancer

Bristol Myers Squibb’s PD-1 blocker Opdivo (nivolumab) failed part B of the Phase III CheckMate-914 study, bearing no significant disease-free survival benefit for patients with localized renal cell carcinoma who are at high-risk of relapse after surgery.

The blockbuster immunotherapy secured separate late-stage victories as an adjuvant-setting treatment in renal cell carcinoma and muscle-invasive urothelial carcinoma.

The drug, branded as Welireg, is used to treat patients with renal cell carcinoma who have received prior treatment.

The new formulation of the drug that was tested in the trial used Halozyme Therapeutics’ (HALO.O) proprietary technology, which allows large volumes of Opdivo, currently administered intravenously, to be delivered as an injection under the skin.

The series of direct-to-consumer oncology advertisements targeting patients with advanced kidney cancer (renal cell carcinoma) and their caregivers.  

Today, the company announced that Part A of the Phase III CheckMate -914 which evaluated the two drugs in combination as an adjuvant treatment for localized renal cell carcinoma (RCC) failed to hit the primary endpoint.